| 2026-04-30 | 10-Q | 10.3 | Amended and Restated Non-Employee Director Compensation Program, effective January 1, 2026 |
|---|
| 2026-04-30 | 10-Q | 10.1 | Second Amendment to the Supply and Packaging Services Agreement, by and between Sandoz GmbH and the Registrant, dated March 23, 2026 |
|---|
| 2026-02-26 | 10-K | 10.38 | Fifth Amendment to the Loan and Security Agreement, dated February 25, 2026, by and among Hercules Capital and the Registrant |
|---|
| 2026-02-26 | 10-K | 10.19 | Revenue Interest Financing Agreement, dated May 3, 2022, by and among NovaQuest Capital Management, Sagard Holding Manager, Hercules Capital and the Registrant |
|---|
| 2025-10-30 | 10-Q | 10.1 | Employment Letter Agreement, dated September 29, 2025, by and between Sanjeev Narula and the Registrant |
|---|
| 2025-08-07 | 10-Q | 10.3 | Employment Letter Agreement, dated June 4, 2025, by and between Anne Marie Cook and the Registrant |
|---|
| 2025-08-07 | 10-Q | 10.2 | Separation Agreement and Release of Claims, dated May 20, 2025, by and between Molly Henderson and the Registrant |
|---|
| 2025-08-07 | 10-Q | 10.1 | Separation Agreement and Release of Claims, dated May 18, 2025, by and between Azmi Nabulsi, M.D., M.P.H. and the Registrant |
|---|
| 2025-05-01 | 10-Q | 10.2 | Separation Agreement, dated April 2, 2025, by and between Terrie Curran and the Registrant |
|---|
| 2025-05-01 | 10-Q | 10.1 | Employment Letter Agreement, dated March 31, 2025, by and between Steven Basta and the Registrant |
|---|
| 2025-03-06 | 10-K | 10.30 | First Amendment to the Supply and Packaging Services Agreement, by and between Sandoz GmbH and the Registrant, dated December 4, 2021 |
|---|
| 2024-11-07 | 10-Q | 10.1 | Letter Agreement to Vonoprazan Commercial Supply Agreement, dated September 4, 2024, by and among Evonik Operations GmbH and the Registrant. |
|---|
| 2024-08-08 | 10-Q | 10.1 | Amended and Restated Non-Employee Director Compensation Program |
|---|
| 2024-06-14 | 10-K/A | 10.28 | Phathom Pharmaceuticals Inc. 2024 Bonus Plan |
|---|
| 2024-06-14 | 10-K/A | 10.27 | Fourth Amendment to the Loan and Security Agreement, dated December 14, 2023, by and among Hercules Capital and the Registrant |
|---|
| 2024-06-14 | 10-K/A | 10.26 | First Amendment to the Commercial Supply Agreement, dated as of December 6, 2023, by and among Catalent Pharma Solutions, LLC and the Registrant |
|---|
| 2024-03-07 | 10-K | 10.28 | Phathom Pharmaceuticals Inc. 2024 Bonus Plan |
|---|
| 2024-03-07 | 10-K | 10.27 | Fourth Amendment to the Loan and Security Agreement, dated December 14, 2023, by and among Hercules Capital and the Registrant |
|---|
| 2024-03-07 | 10-K | 10.26 | First Amendment to the Commercial Supply Agreement, dated as of December 6, 2023, by and among Catalent Pharma Solutions, LLC and the Registrant |
|---|
| 2023-08-10 | 10-Q | 10.2 | Amendment and Restated Non-Employee Director Compensation Program |
|---|
| 2023-08-10 | 10-Q | 10.1 | First Amendment to Vonoprazan Commercial Supply Agreement |
|---|
| 2023-05-10 | 10-Q | 10.1 | Third Amendment to Loan and Security Agreement, dated May 9, 2023, by and among the Registrant and Hercules Capital, Inc. |
|---|
| 2023-02-28 | 10-K | 10.37 | Joinder and Waiver agreement dated October 31, 2022 by and among Hercules Capital, CO Finance LVS XXXVII LLC and the Registrant |
|---|
| 2022-11-09 | 10-Q/A | 10.2 | Second Amendment to the Loan and Security Agreement, dated September 17, 2021, by and among Hercules Capital and the Registrant. |
|---|
| 2022-11-09 | 10-Q/A | 10.1 | Commercial Supply Agreement with Evonik Operations GmbH entered into on August 1, 2022 |
|---|
| 2022-11-08 | 10-Q | 10.2 | Second Amendment to the Loan and Security Agreement, dated September 17, 2021, by and among Hercules Capital and the Registrant. |
|---|
| 2022-11-08 | 10-Q | 10.1 | Commercial Supply Agreement with Evonik Operations GmbH entered into on August 1, 2022 |
|---|
| 2022-08-02 | 10-Q | 10.6 | Transition and Separation Agreement and Release of Claims, dated April 5, 2022, by and between the Registrant and Anthony Guzzo |
|---|
| 2022-08-02 | 10-Q | 10.5 | Amended and Restated Non-Employee Director Compensation Policy |
|---|
| 2022-08-02 | 10-Q | 10.4 | Amendment to the Loan and Security Agreement, dated September 17, 2021, by and among Hercules Capital and the Registrant. |
|---|
| 2022-08-02 | 10-Q | 10.3 | Revenue Interest Financing Agreement, dated May 3, 2022, by and among NovaQuest Capital Management, Sagard Holding Manager, Hercules Capital and the Registrant |
|---|
| 2022-08-02 | 10-Q | 10.2 | Form of Restricted Stock Grant Notice and Restricted Stock Agreement under Phathom Pharmaceuticals, Inc. 2019 Equity Incentive Plan |
|---|
| 2022-05-10 | 10-Q | 10.1 | Employment Letter Agreement, dated March 22, 2022, by and between Molly Henderson and the Company |
|---|
| 2022-03-01 | 10-K | 10.30 | First Amendment to the Supply and Packaging Services Agreement, by and between Sandoz GmbH and the Registrant, dated December 4, 2021 |
|---|
| 2022-01-25 | 8-K | 10.1 | Form of Restricted Stock Unit Agreement under the 2019 Incentive Award Plan. |
|---|
| 2021-11-08 | 10-Q | 10.2 | Warrant to purchase stock issued to Hercules Capital, dated September 17, 2021 |
|---|
| 2021-11-08 | 10-Q | 10.1 | Loan and Security Agreement, dated September 17, 2021, by and among Hercules Capital and the Registrant |
|---|
| 2021-08-10 | 10-Q | 10.5 | Amended and Restated Non-Employee Director Compensation Policy |
|---|
| 2021-08-10 | 10-Q | 10.4 | Commercial Supply Agreement with Catalent Pharma Solutions, LLC entered into on July 2, 2021 |
|---|
| 2021-08-10 | 10-Q | 10.3 | Separation and Release Agreement dated June 4, 2021, between the Registrant and Todd Branning |
|---|
| 2021-08-10 | 10-Q | 10.2 | Third Amendment to the Loan and Security Agreement, dated May 26, 2021, by and among Silicon Valley Bank, SVB Innovation Credit Fund VIII, L.P. and the Registrant |
|---|
| 2021-08-10 | 10-Q | 10.1 | Second Amendment to the Loan and Security Agreement, dated March 11, 2021, by and among Silicon Valley Bank, SVB Innovation Credit Fund VIII, L.P. and the Registrant |
|---|
| 2021-05-11 | 10-Q | 10.1 | Second Amendment to the Loan and Security Agreement, dated March 11, 2021, by and among Silicon Valley Bank, SVB Innovation Credit Fund VIII, L.P. and the Registrant |
|---|
| 2021-03-30 | 10-K | 10.22 | Amendment No. 1 to Commercial Supply Agreement by and between Takeda Pharmaceuticals Company Limited and the Registrant, dated as of December 1, 2020 |
|---|
| 2021-03-30 | 10-K | 10.21 | Supply and Packaging Services Agreement, by and between Sandoz GmbH and the Registrant, dated December 30, 2020 |
|---|
| 2021-03-30 | 10-K | 10.20 | Amendment No. 1 to Takeda License Agreement, dated September 21, 2020 |
|---|
| 2020-11-10 | 10-Q | 10.1 | Amendment No. 1 to Takeda License Agreement, dated September 21, 2020 |
|---|
| 2020-08-06 | 10-Q | 10.4 | Form of Performance Share Unit Grant Notice and Performance Share Unit Agreement under Phathom Pharmaceuticals, Inc. 2019 Incentive Award Plan |
|---|
| 2020-08-06 | 10-Q | 10.3 | Form of Stock Option Grant Notice and Stock Option Agreement under the Phathom Pharmaceuticals, Inc. 2019 Incentive Award Plan |
|---|
| 2020-08-06 | 10-Q | 10.1 | Commercial Supply Agreement, by and between Takeda Pharmaceuticals Company Limited and the Company, dated as of April 30, 2020 |
|---|
| 2020-07-13 | 8-K | 10.1 | Employment Letter Agreement, dated June 25, 2020, by and between Todd Branning and the Company |
|---|
| 2020-05-12 | 10-Q | 10.2 | Amendment to the Loan and Security Agreement, dated March 11, 2020, by and among Silicon Valley Bank, WestRiver Innovation Lending Fund VIII, L.P. and the Registrant |
|---|
| 2020-05-12 | 10-Q | 10.1 | Phathom Pharmaceuticals 2020 Bonus Plan |
|---|